Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0D0LD
|
||||
| Former ID |
DNC006434
|
||||
| Drug Name |
L-873724
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Asthma [ICD10:J45] | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C23H26F3N3O3S
|
||||
| InChI |
InChI=1S/C23H26F3N3O3S/c1-15(2)14-20(22(30)28-13-12-27)29-21(23(24,25)26)18-6-4-16(5-7-18)17-8-10-19(11-9-17)33(3,31)32/h4-11,15,20-21,29H,13-14H2,1-3H3,(H,28,30)/t20-,21-/m0/s1
|
||||
| InChIKey |
VYFDSJLOCIGIKP-SFTDATJTSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Cathepsin K | Target Info | Inhibitor | [2] | |
| Cathepsin L | Target Info | Inhibitor | [3] | ||
| Cathepsin B | Target Info | Inhibitor | [3] | ||
| Cathepsin S | Target Info | Inhibitor | [3] | ||
| KEGG Pathway | Lysosome | ||||
| Osteoclast differentiation | |||||
| Toll-like receptor signaling pathway | |||||
| Rheumatoid arthritishsa04142:Lysosome | |||||
| Phagosome | |||||
| Antigen processing and presentation | |||||
| Proteoglycans in cancer | |||||
| Antigen processing and presentationhsa04142:Lysosome | |||||
| Tuberculosis | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| RANKL Signaling Pathway | |||||
| IL2 Signaling PathwayNetPath_16:IL4 Signaling Pathway | |||||
| TGF_beta_Receptor Signaling PathwayNetPath_11:TCR Signaling Pathway | |||||
| IL2 Signaling PathwayNetPath_22:Leptin Signaling Pathway | |||||
| IL2 Signaling Pathway | |||||
| Reactome | Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| Activation of Matrix Metalloproteinases | |||||
| Trafficking and processing of endosomal TLR | |||||
| MHC class II antigen presentationR-HSA-1236977:Endosomal/Vacuolar pathway | |||||
| Assembly of collagen fibrils and other multimeric structures | |||||
| MHC class II antigen presentationR-HSA-1442490:Collagen degradation | |||||
| MHC class II antigen presentation | |||||
| WikiPathways | RANKL/RANK Signaling Pathway | ||||
| Osteoclast SignalingWP2572:Primary Focal Segmental Glomerulosclerosis FSGSWP2796:Class I MHC mediated antigen processing & presentation | |||||
| Trafficking and processing of endosomal TLR | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7860). | ||||
| REF 2 | The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008 Feb 1;18(3):923-8. Epub 2008 Jan 15. | ||||
| REF 3 | Bioorg Med Chem Lett. 2007 Sep 1;17(17):4929-33. Epub 2007 Jun 10.The identification of potent, selective, and bioavailable cathepsin S inhibitors. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.